ZA200903496B - Spiro-piperidine derivatives as via receptor antagonists - Google Patents

Spiro-piperidine derivatives as via receptor antagonists

Info

Publication number
ZA200903496B
ZA200903496B ZA200903496A ZA200903496A ZA200903496B ZA 200903496 B ZA200903496 B ZA 200903496B ZA 200903496 A ZA200903496 A ZA 200903496A ZA 200903496 A ZA200903496 A ZA 200903496A ZA 200903496 B ZA200903496 B ZA 200903496B
Authority
ZA
South Africa
Prior art keywords
spiro
receptor antagonists
piperidine derivatives
via receptor
piperidine
Prior art date
Application number
ZA200903496A
Other languages
English (en)
Inventor
Caterina Bissantz
Christophe Grundschober
Raffaello Masciadri
Hasane Ratni
Mark Rogers-Evans
Patrick Schnider
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200903496B publication Critical patent/ZA200903496B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA200903496A 2006-12-07 2009-05-20 Spiro-piperidine derivatives as via receptor antagonists ZA200903496B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06125634 2006-12-07

Publications (1)

Publication Number Publication Date
ZA200903496B true ZA200903496B (en) 2010-03-31

Family

ID=39295880

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200903496A ZA200903496B (en) 2006-12-07 2009-05-20 Spiro-piperidine derivatives as via receptor antagonists

Country Status (21)

Country Link
US (3) US20080146568A1 (es)
EP (1) EP2102207B1 (es)
JP (1) JP2010511661A (es)
KR (1) KR101050568B1 (es)
CN (1) CN101547923A (es)
AR (1) AR064135A1 (es)
AT (1) ATE469900T1 (es)
AU (1) AU2007328995B2 (es)
BR (1) BRPI0720004A2 (es)
CA (1) CA2670674A1 (es)
CL (1) CL2007003482A1 (es)
DE (1) DE602007006990D1 (es)
ES (1) ES2344131T3 (es)
IL (1) IL198544A (es)
MX (1) MX2009005504A (es)
NO (1) NO20091830L (es)
PE (1) PE20081252A1 (es)
RU (1) RU2009119394A (es)
TW (1) TW200838518A (es)
WO (1) WO2008068185A1 (es)
ZA (1) ZA200903496B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2535329A3 (en) 2006-12-22 2013-03-27 F. Hoffmann-La Roche AG Spiro-piperidine derivatives
PL2285808T3 (pl) 2008-04-29 2014-04-30 Novartis Ag Spiro-indolowe pochodne do leczenia chorób pasożytniczych
PE20170671A1 (es) * 2014-11-14 2017-05-22 Hoffmann La Roche Espiro-tiazolonas
CN108884096B (zh) * 2016-02-08 2022-03-22 豪夫迈·罗氏有限公司 作为ddr1抑制剂的螺二氢吲哚酮
CN111212842B (zh) * 2017-09-05 2022-10-25 布莱克索恩治疗公司 血管加压素受体拮抗剂以及与其相关的产品和方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3370091A (en) 1964-06-15 1968-02-20 Hoffmann La Roche 2 aminobenzhydrylhalides
US3531467A (en) 1966-12-23 1970-09-29 Hoffmann La Roche Process for the preparation of 2,3,4,5-tetrahydro - 5 - aryl - 1h - 1,4 - benzodiazepine derivatives
US4209625A (en) 1977-04-21 1980-06-24 American Hoechst Corporation Spiro[indoline-3,4'-piperidine]s
DE3818830A1 (de) 1988-06-03 1989-12-14 Boehringer Mannheim Gmbh Bicyclische carboxamide, verfahren zu ihrer herstellung, deren vorstufen, und diese verbindungen enthaltende arzneimittel
CA2037287A1 (en) * 1990-03-02 1991-09-03 Ben E. Evans Spirocyclic oxytocin antagonists
DK78692D0 (da) 1992-06-12 1992-06-12 Lundbeck & Co As H Dimere piperidin- og piperazinderivater
WO1994007496A1 (en) 1992-10-07 1994-04-14 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5670509A (en) * 1993-09-27 1997-09-23 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
IT1271026B (it) 1994-10-21 1997-05-26 Isagro Ricerca Srl Derivati dell'acido b-amminopropionico ad attivita' fungicida
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
EA000992B1 (ru) 1995-12-14 2000-08-28 Мерк Энд Ко., Инк. Антагонисты гормона, высвобождающего гонадотропин
GB9601724D0 (en) 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US6166209A (en) 1997-12-11 2000-12-26 Hoffmann-La Roche Inc. Piperidine derivatives
CO5150201A1 (es) 1998-09-07 2002-04-29 Hoffmann La Roche Derivados de piperidina
TWI279402B (en) 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
GB0003397D0 (en) 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
JP2003532729A (ja) 2000-05-12 2003-11-05 ソルベイ・フアーマシユーチカルズ・ベー・ブイ ピペラジンおよびピペリジン化合物
WO2002028861A2 (en) 2000-09-29 2002-04-11 Eli Lilly And Company Methods and compounds for treating proliferative diseases
BR0214455A (pt) 2001-11-27 2004-11-03 Hoffmann La Roche Derivados benzotiazol
FR2833948B1 (fr) 2001-12-21 2004-02-06 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
US20040152741A1 (en) 2002-09-09 2004-08-05 Nps Allelix Corporation Arylglycine derivatives and their use as glycine transport inhibitors
WO2004026855A1 (en) 2002-09-20 2004-04-01 H. Lundbeck A/S Method for manufacture of dihydroisobenzofuran derivatives
JP2006505570A (ja) 2002-10-17 2006-02-16 アムジエン・インコーポレーテツド ベンズイミダゾール誘導体およびそれのバニロイド受容体リガンドとしての使用
AU2003215549A1 (en) 2003-02-03 2004-08-30 Janssen Pharmaceutica N.V. Mercaptoimidazoles as ccr2 receptor antagonists
US7244852B2 (en) 2003-02-27 2007-07-17 Abbott Laboratories Process for preparing 2-methylpyrrolidine and specific enantiomers thereof
EP2239012A3 (en) * 2003-04-11 2011-06-15 High Point Pharmaceuticals, LLC Substituted amide derivatives and pharmaceutical uses thereof
JP2007510662A (ja) 2003-11-04 2007-04-26 エリクシアー ファーマシューティカルズ， インコーポレイテッド 治療化合物およびその使用
WO2005063754A1 (en) * 2003-12-22 2005-07-14 Pfizer Limited Triazole derivatives as vasopressin antagonists
JP2007516298A (ja) 2003-12-23 2007-06-21 アリーナ ファーマシューティカルズ， インコーポレイテッド 新規なスピロインドリンまたはスピロイソキノリン化合物、それらの使用方法および組成物
GB0400700D0 (en) * 2004-01-13 2004-02-18 Pfizer Ltd Compounds useful in therapy
RU2007106180A (ru) 2004-08-05 2008-09-10 Ф. Хоффманн-Ля Рош Аг (Ch) Производные индола, индазола или индолина
JP2008515956A (ja) 2004-10-12 2008-05-15 ノボ ノルディスク アクティーゼルスカブ １１β−ヒドロキシステロイドデヒドロゲナーゼ１型活性スピロ化合物
CN100551006C (zh) * 2004-10-13 2009-10-14 索尼株式会社 再现装置、成像装置以及屏幕显示方法
WO2006123242A1 (en) 2005-05-18 2006-11-23 Pfizer Limited 1, 2, 4 -triazole derivatives as vasopressin antagonists
US8190027B2 (en) * 2006-07-12 2012-05-29 Tellabs Operations, Inc. Multifunctional and reconfigurable optical node and optical network
PL1904477T3 (pl) 2005-07-14 2009-07-31 Hoffmann La Roche Pochodne indolo-3-karbonylo-spiro-piperydyny jako antagoniści receptora V1a
JP2009507800A (ja) 2005-09-09 2009-02-26 ユーロ−セルティーク エス．エイ． 縮合およびスピロ環化合物ならびにその使用
EP2535329A3 (en) 2006-12-22 2013-03-27 F. Hoffmann-La Roche AG Spiro-piperidine derivatives
ATE486877T1 (de) 2006-12-29 2010-11-15 Hoffmann La Roche Azaspiroderivate
JP2010515700A (ja) 2007-01-12 2010-05-13 エフ．ホフマン−ラ ロシュ アーゲー スピロピペリジングリシンアミド誘導体

Also Published As

Publication number Publication date
JP2010511661A (ja) 2010-04-15
US20080139554A1 (en) 2008-06-12
AR064135A1 (es) 2009-03-18
US8202993B2 (en) 2012-06-19
RU2009119394A (ru) 2011-01-20
MX2009005504A (es) 2009-06-03
EP2102207A1 (en) 2009-09-23
KR101050568B1 (ko) 2011-07-19
WO2008068185A1 (en) 2008-06-12
ES2344131T3 (es) 2010-08-18
EP2102207B1 (en) 2010-06-02
IL198544A (en) 2012-06-28
CA2670674A1 (en) 2008-06-12
PE20081252A1 (es) 2008-09-04
AU2007328995A1 (en) 2008-06-12
US20080139553A1 (en) 2008-06-12
IL198544A0 (en) 2010-02-17
NO20091830L (no) 2009-07-06
ATE469900T1 (de) 2010-06-15
AU2007328995B2 (en) 2012-04-26
CL2007003482A1 (es) 2008-07-04
BRPI0720004A2 (pt) 2013-12-17
US20080146568A1 (en) 2008-06-19
KR20090079255A (ko) 2009-07-21
DE602007006990D1 (de) 2010-07-15
TW200838518A (en) 2008-10-01
CN101547923A (zh) 2009-09-30

Similar Documents

Publication Publication Date Title
ZA200800320B (en) Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists
IL202665A0 (en) Piperidine derivatives useful as orexin receptor antagonists
EP2099454A4 (en) AMINOPYRROLIDINES AS CHEMOKINE RECEPTOR ANTAGONISTS
IL205665A0 (en) Heteroaryl derivatives as orexin receptor antagonists
EP2058304A4 (en) P2X4 RECEPTOR ANTAGONIST
ZA200809275B (en) Substituted spirocyclic CGRP receptor antagonists
IL201112A0 (en) Thiazolidine derivatives as orexin receptor antagonists
IL199015A0 (en) Quinuclidinol derivatives as muscarinic receptor antagonists
ZA200902187B (en) 8-Ethinylxanthine derivatives as selective A2A receptor antagonists
IL200804A0 (en) Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists
HK1136302A1 (en) Progesterone receptor antagonists
AP2008004441A0 (en) Piperdin-4-ylpyrazin-2-ylamine derivatives as fastdissociating dopamine 2 receptor antagonists
AP1983A (en) Carboxamide derivatives as muscarinic receptor antagonists
AP2006003840A0 (en) Indole-2-carboxamidine derivatives as NMDA receptor antagonists
ZA200806065B (en) Oxazoloisoquinoline derivatives as thrombin receptor antagonists
IL178622A0 (en) Piperazinylpiperidine derivatives as chemokine receptor antagonists
IL198542A0 (en) 2-aminoquinolines as 5-ht(5a)receptor antagonists
PT1912976E (pt) Derivados de indol-3-il-carboni-piperidin-benzimidazole como antagonistas dos receptores v1a
IL205949A0 (en) 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists
HUP0501169A3 (en) New phenantridine derivatives as selective bradykinin b1 receptor antagonists
ZA200903499B (en) Indoles which act as via receptor antagonists
ZA200903496B (en) Spiro-piperidine derivatives as via receptor antagonists
ZA200802339B (en) Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists
IL193294A0 (en) Piperidine derivatives as cxcr3 receptor antagonists
IL193295A0 (en) Piperidine derivatives as cxcr3 receptor antagonists